EGFR mutations and lung cancer.

Epidermal growth factor receptor (EGFR) is a transmembrane protein with cytoplasmic kinase activity that transduces important growth factor signaling from the extracellular milieu to the cell. Given that more than 60% of non-small cell lung carcinomas (NSCLCs) express EGFR, EGFR has become an important therapeutic target for the treatment of these tumors. Inhibitors that target the kinase domain of EGFR have been developed and are clinically active. More importantly, such tyrosine kinase inhibitors (TKIs) are especially effective in patients whose tumors harbor activating mutations in the tyrosine kinase domain of the EGFR gene. More recent trials have suggested that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI instead of chemotherapy may be the best choice of treatment. Therefore, mutation testing is mandatory to identify these patients, given that selection based only on clinico-pathologic characteristics is inadequate. We review the role of EGFR mutations in the diagnosis and management of NSCLC.

[1]  S. Monaco,et al.  A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. , 2010, Human pathology.

[2]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Edward S. Kim,et al.  Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Y. Miyagi,et al.  Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. , 2007, American journal of clinical pathology.

[5]  John R. Engen,et al.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M , 2009, Nature.

[6]  A. Gazdar,et al.  Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.

[7]  J. Minna,et al.  Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[8]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[9]  D. Tenen,et al.  Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  L. Norton,et al.  The Epidermal Growth Factor Receptor Modulates the Interaction of E-cadherin with the Actin Cytoskeleton* , 1998, The Journal of Biological Chemistry.

[11]  K. Nishio,et al.  High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients , 2006, Cancer science.

[12]  Takayuki Kosaka,et al.  Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung Adenocarcinoma , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Y. Yarden,et al.  Oncogenic growth factor receptors: implications for signal transduction therapy. , 2004, Seminars in cancer biology.

[14]  M. Meyerson,et al.  A Rapid and Sensitive Enzymatic Method for Epidermal Growth Factor Receptor Mutation Screening , 2006, Clinical Cancer Research.

[15]  A. Marchetti,et al.  Assessing EGFR mutations. , 2006, The New England journal of medicine.

[16]  F. Shepherd,et al.  Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer , 2005, Treatments in respiratory medicine.

[17]  L. Zhang,et al.  The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[19]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[20]  W. Gerald,et al.  Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis , 2008, The American journal of surgical pathology.

[21]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[22]  Ping Yang,et al.  Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. , 2004, The Annals of thoracic surgery.

[23]  T. Chou,et al.  Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[24]  Yih-Leong Chang,et al.  Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer , 2006, International journal of cancer.

[25]  P. Jänne,et al.  Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. , 2006, The Journal of clinical investigation.

[26]  N. Normanno,et al.  The role of the EGFR signaling in tumor microenvironment , 2008, Journal of cellular physiology.

[27]  S. Digumarthy,et al.  Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  William Pao,et al.  Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[31]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[32]  Mayumi Ono,et al.  Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas , 2005, Clinical Cancer Research.

[33]  A. Ardizzoni,et al.  Comparison Between Epidermal Growth Factor Receptor (EGFR) Gene Expression in Primary Non-small Cell Lung Cancer (NSCLC) and in Fine-Needle Aspirates from Distant Metastatic Sites , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[35]  M. Tsao,et al.  Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  Y. Yatabe,et al.  EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.

[37]  Ravi Salgia,et al.  Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. , 2005, Cancer research.

[38]  M. Tsao,et al.  Molecular predictive and prognostic markers in non-small-cell lung cancer. , 2009, The Lancet. Oncology.

[39]  R. Pazdur,et al.  FDA drug approval summary: erlotinib (Tarceva) tablets. , 2005, The oncologist.

[40]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  Y. Yatabe EGFR mutations and the terminal respiratory unit , 2010, Cancer and Metastasis Reviews.

[42]  M. Morita,et al.  Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese. , 2006, Lung cancer.

[43]  Lesley Seymour,et al.  Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Y. Ishikawa,et al.  Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts , 2008, Clinical Cancer Research.

[45]  M. Ostland,et al.  Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  M. Tsao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer: impact of primary or secondary mutations. , 2006, Clinical lung cancer.

[47]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[48]  Lesley Seymour,et al.  Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.

[49]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[50]  J. Soh,et al.  The impact of epidermal growth factor receptor gene status on gefitinib‐treated Japanese patients with non‐small‐cell lung cancer , 2007, International journal of cancer.

[51]  A. Iafrate,et al.  Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. , 2007, The Journal of molecular diagnostics : JMD.

[52]  M. Loda,et al.  Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.

[53]  A. Jimeno,et al.  Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. , 2006, Biochimica et biophysica acta.

[54]  M. Ladanyi,et al.  Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. , 2010, The Journal of molecular diagnostics : JMD.

[55]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[56]  J. Minna,et al.  EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.

[57]  C Summers,et al.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). , 1989, Nucleic acids research.

[58]  J. Woodburn,et al.  The epidermal growth factor receptor and its inhibition in cancer therapy. , 1999, Pharmacology & therapeutics.

[59]  L. Fabbri,et al.  Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung , 2005 .

[60]  Balazs Halmos,et al.  Structure and clinical relevance of the epidermal growth factor receptor in human cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Derek Y. Chiang,et al.  EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer , 2008, Clinical Cancer Research.

[62]  A. Gazdar,et al.  Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers , 2006, International journal of cancer.

[63]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[64]  H. Sasaki,et al.  EGFR and erbB2 mutation status in Japanese lung cancer patients , 2006, International journal of cancer.

[65]  T. Mitsudomi,et al.  Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. , 2008, The Journal of thoracic and cardiovascular surgery.

[66]  P. Jänne,et al.  Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[67]  William Pao,et al.  Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors , 2006, Clinical Cancer Research.

[68]  Young Tae Kim,et al.  Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  William C Hahn,et al.  Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.

[70]  W. Pao,et al.  Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[71]  Y. Ishikawa,et al.  Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. , 2009, Lung cancer.

[72]  M. Ladanyi,et al.  Epidermal Growth Factor Receptor Mutation Testing in Lung Cancer: Searching for the Ideal Method , 2007, Clinical Cancer Research.

[73]  Shih-Feng Tsai,et al.  High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.

[74]  Gayatry Mohapatra,et al.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR , 2005, Nature Genetics.

[75]  Y. Yatabe,et al.  Prognostic implication of the EGFR gene mutations in a large cohort of Japanese patients with early stage lung adenocarcinoma , 2007 .

[76]  Huqun,et al.  Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. , 2005, Cancer research.

[77]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[78]  M. Kondo,et al.  Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. , 2005, Lung cancer.

[79]  C. García-Girón,et al.  Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  Y. Ishikawa,et al.  EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset , 2009, Modern Pathology.

[81]  Young Hak Kim,et al.  Dominant Papillary Subtype Is a Significant Predictor of the Response to Gefitinib in Adenocarcinoma of the Lung , 2004, Clinical Cancer Research.

[82]  Mehmet Toner,et al.  Detection of mutations in EGFR in circulating lung-cancer cells. , 2008, The New England journal of medicine.

[83]  M. Tsao,et al.  Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. , 1998, Lung cancer.

[84]  R. Berbeco,et al.  Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing , 2008, Nature Medicine.

[85]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[86]  F. Hirsch,et al.  Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  T. Shibata,et al.  Detection of EGFR mutations in archived cytologic specimens of non-small cell lung cancer using high-resolution melting analysis. , 2006, American journal of clinical pathology.

[88]  R. Salgia,et al.  Gefitinib response of erlotinib-refractory lung cancer involving meninges—role of EGFR mutation , 2006, Nature Clinical Practice Oncology.

[89]  Takayuki Kosaka,et al.  Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  C. Pirker,et al.  EGFR/KRAS/BRAF Mutations in Primary Lung Adenocarcinomas and Corresponding Locoregional Lymph Node Metastases , 2009, Clinical Cancer Research.

[91]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[92]  K. Nishio,et al.  Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non–Small-Cell Lung Cancer , 2006, Clinical Cancer Research.

[93]  Mengzhao Wang,et al.  Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme , 2004, BMC Cancer.

[94]  R. Herbst,et al.  Targeting the epidermal growth factor receptor in non-small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[95]  William Pao,et al.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  S. Tsai,et al.  Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants , 2006, Oncogene.

[97]  Teruhiko Yoshida,et al.  Prospective Study of the Accuracy of EGFR Mutational Analysis by High-Resolution Melting Analysis in Small Samples Obtained from Patients with Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[98]  K. Nishio,et al.  Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer , 2007, Cancer.

[99]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[100]  J. Crowley,et al.  Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[101]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[102]  D. Whitcombe,et al.  Detection of PCR products using self-probing amplicons and fluorescence , 1999, Nature Biotechnology.

[103]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[104]  I. Wistuba,et al.  Germ-line and somatic presentations of the EGFR T790M mutation in lung cancer. , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[105]  Y. Kim,et al.  Predictors of the Response to Gefitinib in Refractory Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[106]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[107]  Y. Yatabe,et al.  Epidermal growth factor receptor mutations in lung cancers , 2007, Pathology international.

[108]  Mariano Provencio,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[109]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[110]  Patricia L. Harris,et al.  Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  Kikuya Kato,et al.  Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib , 2008, Cancer science.

[112]  D. Haber,et al.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[113]  Elisa Rossi,et al.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. , 2005, Journal of the National Cancer Institute.

[114]  M. Ladanyi,et al.  Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma , 2008, Clinical Cancer Research.

[115]  G. Giaccone,et al.  Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[116]  D. Hwang,et al.  Gastrosplenic fistula from Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[118]  L. Layfield,et al.  Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. , 2006, Human pathology.

[119]  Ming-Sound Tsao,et al.  K-ras mutations in non-small-cell lung carcinoma: a review. , 2006, Clinical lung cancer.

[120]  M. Stack,et al.  Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. , 2001, Cancer research.